US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% META $720.89 ▼-0.06% SPCX $160.57 ▼-4.19%
FinancialContent

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.9774 -0.0226 (-2.26%)
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Ocugen Stock Zoomed 12% Higher Today ↗
A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs. 
Via The Motley Fool
News headline image
Ocugen Shares Are Trading Higher Monday: What's Going On? ↗
Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400. 
Via Benzinga
News headline image
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
From Ocugen
Via GlobeNewswire
News headline image
Demystifying Ocugen: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
A Peek at Ocugen's Future Earnings ↗
 
Via Benzinga
News headline image
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire
News headline image
Ocugen (OCGN) Q2 Revenue Jumps 20% ↗
Via The Motley Fool
News headline image
Ocugen Inc (NASDAQ:OCGN) Q2 2025 Earnings: Revenue Surges, EPS Loss Narrows ↗
Ocugen Inc (OCGN) reports Q2 2025 earnings with $1.37M revenue, beating estimates by 284%, while EPS loss narrows to -$0.05. Progress in gene therapy trials boosts investor optimism. 
Via Chartmill
News headline image
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Earnings Scheduled For August 1, 2025 ↗
 
Via Benzinga
News headline image
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
5 Biotech Stocks with Highly Anticipated Pending Results ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On? ↗
Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics. 
Via Benzinga
News headline image
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
From Ocugen
Via GlobeNewswire
News headline image
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial ↗
Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients who currently have no other options. 
Via Benzinga
News headline image
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen To Present at BIO International Convention 2025
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts ↗
 
Via Benzinga
News headline image
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish ↗
CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three... 
Via Stocktwits
Topics Lawsuit
News headline image
Ocugen Provides Business Update with First Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >